POSTER 67

Zasocitinib (TAK-279), An Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial

Nada Elbuluk, Melinda Gooderham, Jessamyn Blau, Wenwen Zhang, Warren Winkelman and Mark Lebwohl

< Previous Poster | Next Poster >

Poster 67